To the Editor Uncertainty remains around the efficacy of programmed cell death 1 (PD-1) inhibitors for treatment of advanced biliary tract cancer (objective response rate [ORR], 3%-22%).1 Recently, Kim et al2 reported a multicenter phase 2 study of nivolumab in a single group of patients with refractory biliary tract cancer and found an ORR of 22% with a median progression-free survival of 4.0 months. To our knowledge, this is the highest ORR for PD-1/programmed cell death ligand 1 blockade monotherapies achieved in biliary tract cancer, but there are several concerns that should be discussed.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Wang D, Seery S, Zhao H. Need for More Comprehensive Evaluation of Immune-Related Adverse Events in Immunotherapy for Biliary Tract Cancer. JAMA Oncol. 2020;6(12):1981. doi:10.1001/jamaoncol.2020.4815
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: